VRTX
Vertex Pharmaceuticals Incorporated
Price Chart
Latest Quote
$513.75
-3.74 (-0.72%)
Current Price
| Previous Close | $517.49 |
| Open | $514.84 |
| Day High | $514.84 |
| Day Low | $509.20 |
| Volume | 35,525 |
Stock Information
| Shares Outstanding | 253.46M |
| Total Debt | $1.98B |
| Cash Equivalents | $7.85B |
| Revenue | $12.59B |
| Net Income | $4.41B |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $130.22B |
| P/E Ratio | 29.32 |
| EPS (TTM) | $17.52 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $125.29B |
| Sales | $12.59B |
| Income | $4.41B |
| Book/sh | $79.92 |
| Cash/sh | $30.98 |
| Employees | 6K |
Financial Ratios
| Quick Ratio | 2.54 |
| Current Ratio | 3.19 |
| Debt/Eq | 9.77 |
| EPS Growth TTM | 6.50% |
Returns & Margins
| ROA | 11.93% |
| ROE | 23.54% |
| Gross Margin | 54.96% |
| Operating Margin | 38.05% |
| Profit Margin | 35.00% |
Ownership
| Insider Ownership | 0.21% |
| Institutional Ownership | 98.31% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | 25.16 |
| PEG | 2.05 |
| P/S | 10.35 |
| P/B | 6.43 |
Analyst Data
| Recommendation | buy |
| Target Price | $571.46 |
Technical Indicators
| SMA20 | $509.49 |
| SMA50 | $522.91 |
| SMA200 | $477.86 |
| RSI | 53.28 |
| ATR | 14.4511 |
| Shares Float | 252.68M |
| Short Float | 2.01% |
| Short Ratio | 4.39 |
| Volatility | 0.28 |
| Rel Volume | 0.03 |
Performance History
| Week | -0.17% |
| Month | -2.64% |
| Quarter | +6.29% |
| 6 Months | +19.44% |
| YTD | +13.63% |
| Year | +21.92% |
| 3 Years | +41.97% |
| 5 Years | +177.09% |
| 10 Years | +577.41% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-10-27 | $513.75 | 35,525 |
| 2026-10-26 | $517.49 | 1,189,000 |
| 2026-10-23 | $523.93 | 832,600 |
| 2026-10-22 | $535.17 | 1,641,200 |
| 2026-10-21 | $524.52 | 1,448,600 |
| 2026-10-20 | $514.65 | 1,230,000 |
| 2026-10-19 | $501.95 | 1,298,700 |
| 2026-10-16 | $499.74 | 1,413,000 |
| 2026-10-15 | $508.75 | 2,262,500 |
| 2026-10-14 | $498.50 | 2,089,700 |
| 2026-10-13 | $485.22 | 1,187,300 |
| 2026-10-12 | $507.00 | 952,700 |
| 2026-10-09 | $510.08 | 1,480,800 |
| 2026-10-08 | $503.25 | 1,488,000 |
| 2026-10-07 | $505.64 | 806,600 |
| 2026-10-06 | $502.31 | 775,000 |
| 2026-10-05 | $503.50 | 914,900 |
| 2026-10-02 | $504.73 | 939,600 |
| 2026-10-01 | $506.74 | 1,194,400 |
| 2026-09-30 | $522.81 | 1,146,000 |
| 2026-09-29 | $526.73 | 688,800 |
| 2026-09-28 | $527.67 | 823,500 |
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
đ° Latest News
No news articles available at the moment. Check back later for updates on VRTX.
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $1,651,300,000 | $1,530,500,000 | $1,262,200,000 | $1,080,300,000 |
| Cost Of Revenue | $1,651,300,000 | $1,530,500,000 | $1,262,200,000 | $1,080,300,000 |
| Total Revenue | $12,001,300,000 | $11,020,100,000 | $9,869,200,000 | $8,930,700,000 |
| Operating Revenue | $11,970,600,000 | $11,020,100,000 | $9,869,200,000 | $8,930,700,000 |
| Expenses | ||||
| Interest Expense | $13,300,000 | $30,600,000 | $44,100,000 | $54,800,000 |
| Total Expenses | $7,446,900,000 | $11,253,500,000 | $6,088,800,000 | $4,680,800,000 |
| Other Income Expense | $-388,800,000 | $-85,600,000 | $28,800,000 | $-107,300,000 |
| Other Non Operating Income Expenses | $-7,700,000 | $-86,100,000 | $-22,800,000 | $-164,800,000 |
| Net Non Operating Interest Income Expense | $477,600,000 | $567,500,000 | $570,600,000 | $89,800,000 |
| Interest Expense Non Operating | $13,300,000 | $30,600,000 | $44,100,000 | $54,800,000 |
| Operating Expense | $5,795,600,000 | $9,723,000,000 | $4,826,600,000 | $3,600,500,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $3,953,200,000 | $-535,600,000 | $3,619,600,000 | $3,322,000,000 |
| Net Interest Income | $477,600,000 | $567,500,000 | $570,600,000 | $89,800,000 |
| Interest Income | $490,900,000 | $598,100,000 | $614,700,000 | $144,600,000 |
| Normalized Income | $4,277,666,859 | $-535,995,000 | $3,576,978,400 | $3,276,862,500 |
| Net Income From Continuing And Discontinued Operation | $3,953,200,000 | $-535,600,000 | $3,619,600,000 | $3,322,000,000 |
| Total Operating Income As Reported | $4,173,300,000 | $-232,900,000 | $3,832,000,000 | $4,307,400,000 |
| Net Income Common Stockholders | $3,953,200,000 | $-535,600,000 | $3,619,600,000 | $3,322,000,000 |
| Net Income | $3,953,200,000 | $-535,600,000 | $3,619,600,000 | $3,322,000,000 |
| Net Income Including Noncontrolling Interests | $3,953,200,000 | $-535,600,000 | $3,619,600,000 | $3,322,000,000 |
| Net Income Continuous Operations | $3,953,200,000 | $-535,600,000 | $3,619,600,000 | $3,322,000,000 |
| Pretax Income | $4,643,200,000 | $248,500,000 | $4,379,800,000 | $4,232,400,000 |
| Special Income Charges | $-381,100,000 | $500,000 | $51,600,000 | $57,500,000 |
| Interest Income Non Operating | $490,900,000 | $598,100,000 | $614,700,000 | $144,600,000 |
| Operating Income | $4,554,400,000 | $-233,400,000 | $3,780,400,000 | $4,249,900,000 |
| Gross Profit | $10,350,000,000 | $9,489,600,000 | $8,607,000,000 | $7,850,400,000 |
| Per Share | ||||
| Diluted EPS | $15.32 | $-2.08 | $13.89 | $12.82 |
| Basic EPS | $15.46 | $-2.08 | $14.05 | $12.97 |
| Other | ||||
| Tax Effect Of Unusual Items | $-56,633,141 | $105,000 | $8,978,400 | $12,362,500 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $5,247,400,000 | $485,800,000 | $4,553,600,000 | $4,378,000,000 |
| Total Unusual Items | $-381,100,000 | $500,000 | $51,600,000 | $57,500,000 |
| Total Unusual Items Excluding Goodwill | $-381,100,000 | $500,000 | $51,600,000 | $57,500,000 |
| Reconciled Depreciation | $209,800,000 | $207,200,000 | $181,300,000 | $148,300,000 |
| EBITDA (Bullshit earnings) | $4,866,300,000 | $486,300,000 | $4,605,200,000 | $4,435,500,000 |
| EBIT | $4,656,500,000 | $279,100,000 | $4,423,900,000 | $4,287,200,000 |
| Diluted Average Shares | $258,000,000 | $257,900,000 | $260,500,000 | $259,100,000 |
| Basic Average Shares | $255,700,000 | $257,900,000 | $257,700,000 | $256,100,000 |
| Diluted NI Availto Com Stockholders | $3,953,200,000 | $-535,600,000 | $3,619,600,000 | $3,322,000,000 |
| Tax Provision | $690,000,000 | $784,100,000 | $760,200,000 | $910,400,000 |
| Impairment Of Capital Assets | $379,000,000 | $0 | $0 | - |
| Restructuring And Mergern Acquisition | $2,100,000 | $-500,000 | $-51,600,000 | $-57,500,000 |
| Research And Development | $4,042,500,000 | $8,258,700,000 | $3,690,000,000 | $2,655,800,000 |
| Selling General And Administration | $1,753,100,000 | $1,464,300,000 | $1,136,600,000 | $944,700,000 |
| Other Special Charges | - | $4,628,400,000 | $527,100,000 | $115,500,000 |
Fetched: 2026-10-17
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $17,153,600,000 | $14,495,700,000 | $15,652,500,000 | $12,221,100,000 |
| Total Assets | $25,643,000,000 | $22,533,200,000 | $22,730,200,000 | $18,150,900,000 |
| Total Non Current Assets | $14,442,000,000 | $12,936,800,000 | $8,586,000,000 | $4,916,100,000 |
| Other Non Current Assets | $1,236,600,000 | $999,300,000 | $895,300,000 | $409,600,000 |
| Non Current Deferred Assets | $2,897,900,000 | $2,331,100,000 | $1,812,100,000 | $1,246,900,000 |
| Non Current Deferred Taxes Assets | $2,897,900,000 | $2,331,100,000 | $1,812,100,000 | $1,246,900,000 |
| Investmentin Financial Assets | $5,712,300,000 | $5,107,900,000 | $2,497,800,000 | $112,200,000 |
| Goodwill And Other Intangible Assets | $1,512,200,000 | $1,913,900,000 | $1,927,900,000 | $1,691,600,000 |
| Other Intangible Assets | $424,200,000 | $825,900,000 | $839,900,000 | $603,600,000 |
| Current Assets | $11,201,000,000 | $9,596,400,000 | $14,144,200,000 | $13,234,800,000 |
| Other Current Assets | $110,900,000 | $76,400,000 | $84,300,000 | $74,400,000 |
| Hedging Assets Current | $6,200,000 | $130,100,000 | $1,800,000 | $47,500,000 |
| Prepaid Assets | $736,200,000 | $459,200,000 | $537,600,000 | $431,600,000 |
| Inventory | $1,686,800,000 | $1,205,400,000 | $738,800,000 | $460,600,000 |
| Receivables | $2,052,800,000 | $1,609,400,000 | $1,563,400,000 | $1,442,200,000 |
| Accounts Receivable | $2,052,800,000 | $1,609,400,000 | $1,563,400,000 | $1,442,200,000 |
| Cash Cash Equivalents And Short Term Investments | $6,608,100,000 | $6,115,900,000 | $11,218,300,000 | $10,778,500,000 |
| Cash And Cash Equivalents | $5,084,800,000 | $4,569,600,000 | $10,369,100,000 | $10,504,000,000 |
| Debt | ||||
| Total Debt | $2,030,500,000 | $1,744,300,000 | $808,400,000 | $899,700,000 |
| Long Term Debt And Capital Lease Obligation | $1,953,200,000 | $1,657,200,000 | $724,700,000 | $810,300,000 |
| Current Debt And Capital Lease Obligation | $77,300,000 | $87,100,000 | $83,700,000 | $89,400,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $6,977,200,000 | $6,123,600,000 | $5,149,800,000 | $4,238,200,000 |
| Total Non Current Liabilities Net Minority Interest | $3,116,000,000 | $2,559,000,000 | $1,602,400,000 | $1,496,100,000 |
| Other Non Current Liabilities | $267,400,000 | $203,200,000 | $196,300,000 | $233,000,000 |
| Tradeand Other Payables Non Current | $895,400,000 | $698,600,000 | $681,400,000 | $452,800,000 |
| Current Liabilities | $3,861,200,000 | $3,564,600,000 | $3,547,400,000 | $2,742,100,000 |
| Other Current Liabilities | $127,700,000 | $36,600,000 | $50,700,000 | $62,500,000 |
| Current Deferred Liabilities | $171,800,000 | $206,800,000 | $170,300,000 | $159,600,000 |
| Payables And Accrued Expenses | $3,484,400,000 | $3,234,100,000 | $3,242,700,000 | $2,430,600,000 |
| Payables | $893,000,000 | $877,600,000 | $924,500,000 | $642,200,000 |
| Other Payable | $328,200,000 | $303,500,000 | $460,100,000 | $215,000,000 |
| Total Tax Payable | $103,100,000 | $161,100,000 | $99,500,000 | $123,300,000 |
| Accounts Payable | $461,700,000 | $413,000,000 | $364,900,000 | $303,900,000 |
| Equity | ||||
| Common Stock Equity | $18,665,800,000 | $16,409,600,000 | $17,580,400,000 | $13,912,700,000 |
| Total Equity Gross Minority Interest | $18,665,800,000 | $16,409,600,000 | $17,580,400,000 | $13,912,700,000 |
| Stockholders Equity | $18,665,800,000 | $16,409,600,000 | $17,580,400,000 | $13,912,700,000 |
| Gains Losses Not Affecting Retained Earnings | $-15,900,000 | $127,800,000 | $-14,300,000 | $800,000 |
| Other Equity Adjustments | $-15,900,000 | $127,800,000 | $-14,300,000 | $800,000 |
| Retained Earnings | $13,560,000,000 | $9,606,800,000 | $10,142,400,000 | $6,522,800,000 |
| Other | ||||
| Ordinary Shares Number | $253,991,224 | $256,940,382 | $257,695,221 | $257,011,628 |
| Share Issued | $253,991,224 | $256,940,382 | $257,695,221 | $257,011,628 |
| Tangible Book Value | $17,153,600,000 | $14,495,700,000 | $15,652,500,000 | $12,221,100,000 |
| Invested Capital | $18,665,800,000 | $16,409,600,000 | $17,580,400,000 | $13,912,700,000 |
| Working Capital | $7,339,800,000 | $6,031,800,000 | $10,596,800,000 | $10,492,700,000 |
| Capital Lease Obligations | $2,030,500,000 | $1,744,300,000 | $808,400,000 | $899,700,000 |
| Total Capitalization | $18,665,800,000 | $16,409,600,000 | $17,580,400,000 | $13,912,700,000 |
| Additional Paid In Capital | $5,119,200,000 | $6,672,400,000 | $7,449,700,000 | $7,386,500,000 |
| Capital Stock | $2,500,000 | $2,600,000 | $2,600,000 | $2,600,000 |
| Common Stock | $2,500,000 | $2,600,000 | $2,600,000 | $2,600,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $1,953,200,000 | $1,657,200,000 | $724,700,000 | $810,300,000 |
| Current Deferred Revenue | $171,800,000 | $206,800,000 | $170,300,000 | $159,600,000 |
| Current Capital Lease Obligation | $77,300,000 | $87,100,000 | $83,700,000 | $89,400,000 |
| Current Accrued Expenses | $2,591,400,000 | $2,356,500,000 | $2,318,200,000 | $1,788,400,000 |
| Investments And Advances | $5,712,300,000 | $5,107,900,000 | $2,497,800,000 | $112,200,000 |
| Available For Sale Securities | $5,712,300,000 | $5,107,900,000 | $2,497,800,000 | $112,200,000 |
| Goodwill | $1,088,000,000 | $1,088,000,000 | $1,088,000,000 | $1,088,000,000 |
| Net PPE | $3,083,000,000 | $2,584,600,000 | $1,452,900,000 | $1,455,800,000 |
| Accumulated Depreciation | $-1,204,100,000 | $-1,064,800,000 | $-1,188,900,000 | $-1,027,300,000 |
| Gross PPE | $4,287,100,000 | $3,649,400,000 | $2,641,800,000 | $2,483,100,000 |
| Leases | $1,009,300,000 | $737,600,000 | $474,600,000 | $410,900,000 |
| Other Properties | $1,562,700,000 | $1,356,800,000 | $293,600,000 | $347,400,000 |
| Machinery Furniture Equipment | $1,198,200,000 | $1,060,700,000 | $911,900,000 | $788,600,000 |
| Buildings And Improvements | $483,800,000 | $461,200,000 | $928,600,000 | $903,100,000 |
| Land And Improvements | $33,100,000 | $33,100,000 | $33,100,000 | $33,100,000 |
| Properties | $0 | $0 | $0 | $0 |
| Finished Goods | $230,100,000 | $184,600,000 | $135,000,000 | $161,800,000 |
| Work In Process | $1,196,900,000 | $768,800,000 | $525,100,000 | $260,700,000 |
| Raw Materials | $259,800,000 | $252,000,000 | $78,700,000 | $38,100,000 |
| Other Short Term Investments | $1,523,300,000 | $1,546,300,000 | $849,200,000 | $274,500,000 |
| Treasury Shares Number | - | - | $0 | $0 |
Fetched: 2026-10-17
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $3,193,800,000 | $-978,000,000 | $3,278,900,000 | $3,925,200,000 |
| Operating Activities | ||||
| Operating Cash Flow | $3,631,400,000 | $-492,600,000 | $3,537,300,000 | $4,129,900,000 |
| Cash Flow From Continuing Operating Activities | $3,631,400,000 | $-492,600,000 | $3,537,300,000 | $4,129,900,000 |
| Operating Gains Losses | - | $57,700,000 | $600,000 | $149,100,000 |
| Investing Activities | ||||
| Capital Expenditure | $-437,600,000 | $-485,400,000 | $-258,400,000 | $-204,700,000 |
| Investing Cash Flow | $-945,400,000 | $-3,770,000,000 | $-3,141,700,000 | $-321,100,000 |
| Cash Flow From Continuing Investing Activities | $-945,400,000 | $-3,770,000,000 | $-3,141,700,000 | $-321,100,000 |
| Net Other Investing Changes | $-24,700,000 | $-54,000,000 | $-31,000,000 | $-47,800,000 |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $-2,387,300,000 | $-1,582,100,000 | $-653,700,000 | $-172,000,000 |
| Financing Cash Flow | $-2,261,300,000 | $-1,494,900,000 | $-562,200,000 | $-67,700,000 |
| Cash Flow From Continuing Financing Activities | $-2,261,300,000 | $-1,494,900,000 | $-562,200,000 | $-67,700,000 |
| Net Other Financing Charges | $3,700,000 | $6,200,000 | $1,800,000 | $3,500,000 |
| Net Common Stock Issuance | $-2,387,300,000 | $-1,582,100,000 | $-653,700,000 | $-172,000,000 |
| Other | ||||
| Repayment Of Debt | $-5,400,000 | $-33,600,000 | $-44,900,000 | $-85,500,000 |
| Interest Paid Supplemental Data | $12,400,000 | $30,500,000 | $43,100,000 | $52,300,000 |
| Income Tax Paid Supplemental Data | $1,566,700,000 | $1,082,100,000 | $1,677,300,000 | $1,057,800,000 |
| End Cash Position | $5,087,800,000 | $4,572,200,000 | $10,372,300,000 | $10,512,000,000 |
| Beginning Cash Position | $4,572,200,000 | $10,372,300,000 | $10,512,000,000 | $6,800,100,000 |
| Effect Of Exchange Rate Changes | $90,900,000 | $-42,600,000 | $26,900,000 | $-29,200,000 |
| Changes In Cash | $424,700,000 | $-5,757,500,000 | $-166,600,000 | $3,741,100,000 |
| Proceeds From Stock Option Exercised | $127,700,000 | $114,600,000 | $134,600,000 | $186,300,000 |
| Common Stock Payments | $-2,387,300,000 | $-1,582,100,000 | $-653,700,000 | $-172,000,000 |
| Net Issuance Payments Of Debt | $-5,400,000 | $-33,600,000 | $-44,900,000 | $-85,500,000 |
| Net Long Term Debt Issuance | $-5,400,000 | $-33,600,000 | $-44,900,000 | $-85,500,000 |
| Long Term Debt Payments | $-5,400,000 | $-33,600,000 | $-44,900,000 | $-85,500,000 |
| Net Investment Purchase And Sale | $-483,100,000 | $-3,230,600,000 | $-2,852,300,000 | $227,300,000 |
| Sale Of Investment | $5,913,400,000 | $4,465,600,000 | $934,200,000 | $920,000,000 |
| Purchase Of Investment | $-6,396,500,000 | $-7,696,200,000 | $-3,786,500,000 | $-692,700,000 |
| Net Intangibles Purchase And Sale | $0 | $-187,700,000 | $-58,000,000 | $0 |
| Purchase Of Intangibles | $0 | $-187,700,000 | $-58,000,000 | $0 |
| Net PPE Purchase And Sale | $-437,600,000 | $-297,700,000 | $-200,400,000 | $-204,700,000 |
| Purchase Of PPE | $-437,600,000 | $-297,700,000 | $-200,400,000 | $-204,700,000 |
| Change In Working Capital | $-1,199,100,000 | $-514,800,000 | $-265,700,000 | $340,800,000 |
| Change In Other Current Liabilities | $148,500,000 | $39,700,000 | $208,900,000 | $498,900,000 |
| Change In Payables And Accrued Expense | $-80,100,000 | $262,400,000 | $478,100,000 | $663,300,000 |
| Change In Accrued Expense | $-116,900,000 | $212,900,000 | $429,400,000 | $542,500,000 |
| Change In Payable | $36,800,000 | $49,500,000 | $48,700,000 | $120,800,000 |
| Change In Account Payable | $36,800,000 | $49,500,000 | $48,700,000 | $120,800,000 |
| Change In Prepaid Assets | $-396,000,000 | $-200,300,000 | $-545,700,000 | $-326,400,000 |
| Change In Inventory | $-524,200,000 | $-517,300,000 | $-322,900,000 | $-136,400,000 |
| Change In Receivables | $-347,300,000 | $-99,300,000 | $-84,100,000 | $-358,600,000 |
| Changes In Account Receivables | $-347,300,000 | $-99,300,000 | $-84,100,000 | $-358,600,000 |
| Other Non Cash Items | $113,400,000 | $900,000 | $-42,600,000 | $-45,700,000 |
| Stock Based Compensation | $685,900,000 | $698,500,000 | $581,200,000 | $491,300,000 |
| Asset Impairment Charge | $379,000,000 | $0 | $0 | - |
| Deferred Tax | $-510,800,000 | $-348,800,000 | $-536,500,000 | $-275,900,000 |
| Deferred Income Tax | $-510,800,000 | $-348,800,000 | $-536,500,000 | $-275,900,000 |
| Depreciation Amortization Depletion | $209,800,000 | $207,200,000 | $181,300,000 | $148,300,000 |
| Depreciation And Amortization | $209,800,000 | $207,200,000 | $181,300,000 | $148,300,000 |
| Net Income From Continuing Operations | $3,953,200,000 | $-535,600,000 | $3,619,600,000 | $3,322,000,000 |
| Net Business Purchase And Sale | - | $0 | $0 | $-295,900,000 |
| Purchase Of Business | - | $0 | $0 | $-295,900,000 |
| Gain Loss On Investment Securities | - | $57,700,000 | $600,000 | $149,100,000 |
| Issuance Of Debt | - | - | $1,800,000 | $0 |
| Long Term Debt Issuance | - | - | $1,800,000 | $0 |
| Depreciation | - | - | - | $148,300,000 |
Fetched: 2026-10-17